```html

Zollinger‑Ellison‑Associated Gastric Hyperacidity

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (known as gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive gastrin, a hormone that stimulates the parietal cells of the stomach to produce large amounts of hydrochloric acid. The resulting gastric hyperacidity can lead to severe peptic ulcers, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years. Both sexes are affected, with a slight male predominance (approximately 55 % male).
Prevalence: The incidence of gastrinomas is estimated at 0.5–2 cases per million people per year, making ZES one of the rarest endocrine disorders of the gastrointestinal tract (CDC, Mayo Clinic).

Symptoms

Because the hallmark of ZES is extreme acid production, symptoms revolve around acid‑related damage to the gastrointestinal (GI) tract.

• Refractory peptic ulcers – ulcers that fail to heal after standard therapy and often appear in atypical locations (duodenum beyond the bulb, jejunum, or even the colon).
• Abdominal pain – usually epigastric, burning, and may worsen after meals.
• Chronic diarrhea – 2–5 loose stools per day; the acid inactivates pancreatic enzymes, leading to fat malabsorption.
• Steatorrhea – greasy, foul‑smelling stools caused by malabsorbed fats.
• Weight loss – secondary to malabsorption and reduced intake because of pain.
• Nausea & vomiting – especially when ulcers bleed or cause obstruction.
• Gastroesophageal reflux disease (GERD) – due to excess acid spilling into the esophagus.
• Upper GI bleeding – melena or hematemesis from ulcer erosion.
• Fatigue & anemia – chronic blood loss or iron malabsorption.
• Enuresis or nocturnal diarrhea – more common in children with ZES.

Causes and Risk Factors

Zollinger‑Ellison syndrome is caused by gastrin‑secreting neuroendocrine tumors.

Primary causes

• Solitary gastrinoma – most common; usually located in the “gastrinoma triangle” (duodenum, pancreatic head, and the junction of the cystic and common bile ducts).
• Multiple endocrine neoplasia type 1 (MEN‑1) – an inherited syndrome (autosomal dominant) that predisposes to gastrinomas, parathyroid adenomas, and pituitary tumors. About 20–25 % of ZES patients have MEN‑1.

Risk factors

• Family history of MEN‑1 or known gastrinoma.
• Genetic mutations in the MEN1 gene.
• Age > 30 years (most cases).
• Male sex (slight predominance).
• Smoking – may increase neuroendocrine tumor risk, although data are limited.

Diagnosis

Diagnosing ZES requires confirming both hypergastrinemia and the presence of a gastrinoma, while excluding other causes of high gastrin.

Laboratory tests

• Fasting serum gastrin level – values > 1,000 pg/mL are highly suggestive. Levels between 100–1,000 pg/mL require further testing.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin is > 120 pg/mL, confirming gastrinoma.
• Basic metabolic panel, CBC, and iron studies – to assess for anemia or electrolyte loss.

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution detection of small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – for tumor localization and staging.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – highly sensitive for neuroendocrine tumors and metastatic disease.
• Upper endoscopy (EGD) – visualizes ulcers and may obtain biopsies to rule out malignancy.

Diagnostic criteria (summary)

1. Fasting gastrin > 100 pg/mL with gastric pH < 2 (or secretin test positivity).
2. Identification of a gastrinoma on imaging or intra‑operative exploration.
3. Exclusion of other causes of hypergastrinemia (e.g., chronic atrophic gastritis, PPI use, renal failure).

Treatment Options

Management targets two goals: control of acid hypersecretion and eradication or control of the tumor.

Acid‑blocking therapy

• High‑dose proton pump inhibitors (PPIs) – omeprazole, esomeprazole, rabeprazole, or pantoprazole 60–120 mg daily (or equivalent). PPIs are the mainstay and often normalize gastric pH within days (Cleveland Clinic).
• H2‑receptor antagonists – may be added for breakthrough symptoms, but are less effective than PPIs.
• Patients usually remain on lifelong high‑dose PPI therapy because gastrin levels often stay elevated.

Surgical management

• Enucleation or segmental resection of localized gastrinomas – preferred when disease is confined and the tumor is <5 cm.
• Pancreaticoduodenectomy (Whipple procedure) – for larger or multiple tumors involving the pancreatic head.
• Debulking surgery – may reduce tumor burden in metastatic disease to improve symptom control.

Medical therapy for tumor control

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release, shrink some tumors, and control symptoms in metastatic ZES.
• Targeted therapy – everolimus or sunitinib for progressive, unresectable neuroendocrine tumors (per NCCN guidelines).
• Chemotherapy – generally limited to high‑grade neuroendocrine carcinomas; not first‑line for typical gastrinomas.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor‑positive metastatic disease.

Lifestyle and adjunct measures

• Avoid NSAIDs, aspirin, and other ulcerogenic medications.
• Stop smoking – improves ulcer healing.
• Limit alcohol, caffeine, and very spicy foods that can aggravate acid secretion.
• Small, frequent meals may reduce symptom burden.

Living with Zollinger‑Ellison‑Associated Gastric Hyperacidity

Even after tumor treatment, most patients require lifelong acid suppression. The following practical tips help maintain quality of life.

Medication adherence

• Take PPIs exactly as prescribed (usually before breakfast). Missing doses can rapidly lower gastric pH and trigger ulcer pain.
• Keep a medication log or use a smartphone reminder.

Nutrition

• Choose a diet low in irritating substances: avoid citrus, tomato‑based sauces, chocolate, and carbonated drinks.
• Incorporate soluble fiber (oats, apples, carrots) which can buffer acid.
• If steatorrhea is present, a low‑fat diet (≤ 30 % of calories) and medium‑chain triglyceride (MCT) oil may improve stool consistency.
• Consider a vitamin B12 supplement, as chronic acid suppression can impair B12 absorption.

Monitoring & follow‑up

• Blood work every 6–12 months: gastrin level, liver function, and nutritional panels.
• Imaging (CT/MRI or DOTATATE PET) annually if tumors are unresectable or metastatic.
• Endoscopic surveillance every 1–2 years to assess ulcer healing.

Psychosocial support

• Join patient support groups (e.g., NETpatient.org) to share experiences.
• Seek counseling if chronic pain or medication burden leads to anxiety or depression.

Prevention

Because ZES is largely driven by tumor biology, primary prevention is limited. However, steps can reduce the impact of hyperacidity and lower the risk of complications.

• Prompt evaluation of persistent or recurrent ulcer disease—early diagnosis prevents severe acid‑related damage.
• Screen family members for MEN‑1 if a known mutation exists; genetic counseling can guide surveillance.
• Maintain a healthy weight and avoid smoking, which are general risk‑reduction strategies for neuroendocrine tumors.

Complications

If untreated or inadequately controlled, gastric hyperacidity in ZES can lead to serious health problems.

• Perforated peptic ulcer – emergency situation with risk of peritonitis.
• Upper GI bleeding – may require transfusion or endoscopic hemostasis.
• Gastro‑intestinal obstruction – from ulcer scarring or tumor mass effect.
• Malabsorption and nutritional deficiencies – iron, calcium, magnesium, fat‑soluble vitamins (A, D, E, K).
• Metastatic disease – liver, lymph nodes, or bone involvement in 40–50 % of patients at diagnosis.
• Recurrent ulcer disease – can lead to chronic pain and reduced quality of life.
• Secondary infections – due to chronic PPI use (e.g., Clostridioides difficile).

When to Seek Emergency Care

---

References: Mayo Clinic. Zollinger‑Ellison syndrome. 2023; CDC. Neuroendocrine Tumors Fact Sheet. 2022; NIH National Cancer Institute. Gastric Neuroendocrine Tumors. 2021; Cleveland Clinic. Management of Acid‑Related Diseases. 2022; WHO. Classification of Neuroendocrine Tumors. 2021.

```